Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 5:46 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 48,450 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: AS+ Clear all
Completed Phase 2 Interventional

Docetaxel and Carboplatin in Treating Women With Metastatic Breast Cancer

NCT00005963
View directory record Official record
Conditions
Breast Cancer
Interventions
carboplatin, docetaxel
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
21
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Nov 2, 2026, 5:46 PM EST
Completed Not applicable Interventional Results available

Self-management Intervention for Children With Chronic Medical Complexity: Pilot Feasibility Trial

NCT04470193
View directory record Official record
Conditions
Children With Medical Complexity
Interventions
MyChildCMC app
Other
Lead sponsor
University of Utah
Other
Eligibility
1 Year to 20 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 4, 2024 · Synced Nov 2, 2026, 5:46 PM EST
Completed Phase 1 Interventional Results available

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

NCT02903914
View directory record Official record
Conditions
Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer, Head and Neck Cancer, Lung Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, UC (Urothelial Cancer), Mesothelioma
Interventions
INCB001158, Pembrolizumab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
13
States / cities
Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Nov 2, 2026, 5:46 PM EST
Completed Phase 1 Interventional

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

NCT01042704
View directory record Official record
Conditions
Myeloma
Interventions
Bendamustine, Lenalidomide, Dexamethasone, Aspirin, Prophylaxis, Antibiotic, Biweekly Follow Up, Cyclical Follow Up, Restaging, Post-Treatment Follow Up
Drug · Other
Lead sponsor
Robert Redner, MD
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
22
States / cities
Detroit, Michigan • Steubenville, Ohio • Beaver, Pennsylvania + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Nov 2, 2026, 5:46 PM EST
Recruiting Phase 4 Interventional

Effects of Photobiomodulation (PBM) on Pain After Presentation of Aphthous Ulcers in Pediatric Dental Patients

NCT06819033
View directory record Official record
Conditions
Aphthous Ulcer
Interventions
PBM Therapy, Maalox plus Benadryl
Device · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
5 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Nov 2, 2026, 5:46 PM EST
Completed Not applicable Interventional Results available

Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)

NCT00525733
View directory record Official record
Conditions
HIV Infections
Interventions
darunavir 800 mg, FTC 200 mg/TDF 300mg, Maraviroc, Raltegravir, Ritonavir 100 mg
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Nov 2, 2026, 5:46 PM EST
Not listed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study Investigating the Safety, Tolerability, and PK of XC130-A10H in Healthy Adult Subjects

NCT04043338
View directory record Official record
Conditions
Parkinson's Disease
Interventions
XC130-A10H, Placebo
Drug
Lead sponsor
Xoc Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Nov 2, 2026, 5:46 PM EST
Not listed Not applicable Interventional

Dietary Sodium (DS) Intervention to Reduce Volume Overload and Tissue Sodium in Magnetic Resonance Imaging (MRI) for Hemodialysis (HD) Patients

NCT03189758
View directory record Official record
Conditions
Kidney Failure, Chronic, Dietary Modification
Interventions
Observational Control Diet, Controlled Dietary Sodium Restriction
Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Nov 2, 2026, 5:46 PM EST
Terminated Not applicable Interventional Results available

Gastrointestinal Tract Recovery in Patients Undergoing Open Ventral Hernia Repair

NCT02379858
View directory record Official record
Conditions
Ventral Hernia
Interventions
Alvimopan, Placebo
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Nov 2, 2026, 5:46 PM EST
Completed Not applicable Interventional

Moderating the Negative Impact of Abnormal Screening Mammograms

NCT01153126
View directory record Official record
Conditions
Breast Cancer
Interventions
Comprehensive Health Enhancement Support System (CHESS.)
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Nov 2, 2026, 5:46 PM EST
Completed Phase 2 Interventional Results available

Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration

NCT02564978
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Minocycline
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Nov 2, 2026, 5:46 PM EST
Completed Phase 2 Interventional

Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy

NCT03616834
View directory record Official record
Conditions
Solid Tumors
Interventions
Tomivosertib (eFT-508)
Drug
Lead sponsor
Effector Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
19
States / cities
Tucson, Arizona • Long Beach, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Nov 2, 2026, 5:46 PM EST
Withdrawn Not applicable Interventional Accepts healthy volunteers

Comparison of Quantitative MRI Perfusion Methods With Quantitative PET Perfusion Imaging

NCT02608944
View directory record Official record
Conditions
MRI Scans
Interventions
Adenosine, Regadenoson, O-15 labeled radioactive water, MRI, PET Imaging
Drug · Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 14, 2020 · Synced Nov 2, 2026, 5:46 PM EST
Completed Not applicable Interventional

Preserved Umbilical Vein Use as Autologous Shunt Conduits in Neonatal Cardiac Surgery

NCT02766998
View directory record Official record
Conditions
Congenital Heart Defects
Interventions
Preserved umbilical vein as shunt/conduit
Procedure
Lead sponsor
Boston Children's Hospital
Other
Eligibility
0 Days to 1 Day
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Nov 2, 2026, 5:46 PM EST
Recruiting Not applicable Interventional

Peer Support for Liver Transplant Recipients With History of ALD

NCT07397598
View directory record Official record
Conditions
Alcohol Use Disorder, Alcohol Related Liver Disease, Liver Transplant Recipient
Interventions
Peer Support
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 2, 2026, 5:46 PM EST
Terminated No phase listed Observational Results available

Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment

NCT02614898
View directory record Official record
Conditions
Atypical Hemolytic Uremic Syndrome
Interventions
Eculizumab
Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Nov 2, 2026, 5:46 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Children

NCT01652287
View directory record Official record
Conditions
Children
Interventions
BB-12 supplemented strawberry yogurt, Strawberry flavored yogurt
Drug · Other
Lead sponsor
Georgetown University
Other
Eligibility
1 Year to 5 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Nov 2, 2026, 5:46 PM EST
Completed Phase 2 Interventional Results available

A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache

NCT02163993
View directory record Official record
Conditions
Migraine Headache
Interventions
Galcanezumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
40
States / cities
Gilbert, Arizona • Phoenix, Arizona • Encino, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2018 · Synced Nov 2, 2026, 5:46 PM EST
Active, not recruiting Not applicable Interventional

Developing an Opioid Taper Intervention Before Total Joint Arthroplasty

NCT05788016
View directory record Official record
Conditions
Arthritis Knee, Arthritis Hip, Chronic Pain
Interventions
opioid taper
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 2, 2026, 5:46 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effect of Repeated Prefrontal Cortex Stimulation on Antisocial and Aggressive Behavior

NCT02674516
View directory record Official record
Conditions
Antisocial Behavior, Aggression
Interventions
Transcranial direct current stimulation, Sham transcranial direct current stimulation
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Nov 2, 2026, 5:46 PM EST
Active, not recruiting No phase listed Observational

A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women With an Ovarian Mass

NCT06566716
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
CleoDX ovarian cancer test
Diagnostic Test
Lead sponsor
Cleo Diagnostics Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
19
States / cities
Chandler, Arizona • Jacksonville, Florida • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 2, 2026, 5:46 PM EST
Terminated Phase 2 Interventional Results available

Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder

NCT01382706
View directory record Official record
Conditions
Recurrent Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder
Interventions
docetaxel, lapatinib ditosylate, immunohistochemistry staining method, fluorescence in situ hybridization, laboratory biomarker analysis
Drug · Other · Genetic
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Nov 2, 2026, 5:46 PM EST
Completed Phase 3 Interventional Results available

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

NCT00877006
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
Interventions
bendamustine, rituximab, vincristine, prednisone, cyclophosphamide, doxorubicin
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
79
States / cities
Tucson, Arizona • Little Rock, Arkansas • Corona, California + 70 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Nov 2, 2026, 5:46 PM EST
Terminated Phase 4 Interventional

Adrenal Insufficiency in Septic Shock

NCT00842933
View directory record Official record
Conditions
Septic Shock, Acute Adrenal Insufficiency
Interventions
Corticosteroid
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2011 · Synced Nov 2, 2026, 5:46 PM EST